Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma

被引:7
|
作者
Storandt, Michael H. [1 ]
Gile, Jennifer J. [2 ]
Palmer, Mathias E. [1 ]
Zemla, Tyler J. [3 ]
Ahn, Daniel H. [4 ]
Bekaii-Saab, Tanios S. [4 ]
Jin, Zhaohui [2 ]
Tran, Nguyen H. [2 ]
Mahipal, Amit [2 ,5 ,6 ]
机构
[1] Mayo Clin, Dept Med, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Clin Trials & Biostat, Rochester, MN 55905 USA
[4] Mayo Clin, Dept Hematol Oncol, Phoenix, AZ 85054 USA
[5] Univ Hosp Seidman Canc Ctr, Dept Oncol, Cleveland, OH 44106 USA
[6] Case Western Reserve Univ, Cleveland, OH 44106 USA
基金
美国国家卫生研究院;
关键词
hepatocellular cancer; cabozantinib; immunotherapy; DOUBLE-BLIND; SORAFENIB; ATEZOLIZUMAB; METASTASIS; VEGFR2;
D O I
10.3390/cancers14215173
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Management of hepatocellular carcinoma is a rapidly evolving field, with atezolizumab-bevacizumab recently becoming standard of care after showing survival benefit over sorafenib. However, all clinical trials evaluating drugs approved in the second line setting, such as cabozantinib, have been evaluated following progression on sorafenib, not immunotherapy. We sought to determine if cabozantinib is a viable option for patients after progression on immunotherapy. We conducted a retrospective analysis of patients seen at our institution who had disease progression on immunotherapy and subsequently received cabozantinib, reporting patient survival and tolerance of treatment. We found that patients had a median progression free survival of 2.1 months and median overall survival of 7.7 months, and most patients had a manageable side effect profile, suggesting that cabozantinib is a viable treatment option following progression on immunotherapy. (1) Background: Cabozantinib, a multikinase inhibitor, is approved by the Food and Drug Administration (FDA) for the treatment of advanced hepatocellular carcinoma (HCC) following progression on sorafenib. Recently, atezolizumab plus bevacizumab has been approved in the first line setting for advanced HCC and has become the new standard of care. Whether cabozantinib improves outcomes following progression on immunotherapy remains unknown. We describe the clinical outcomes following treatment with immunotherapy in patients with advanced HCC who received cabozantinib. (2) Methods: We conducted a multicentric, retrospective analysis of patients with advanced HCC diagnosed between 2010-2021 at Mayo Clinic in Minnesota, Arizona, and Florida who received cabozantinib. Median overall survival and progression free survival analyses were performed using the Kaplan-Meier method. Adverse events were determined using Common Terminology Criteria for Adverse Events (CTCAE). (3). Results: We identified 26 patients with advanced HCC who received cabozantinib following progression on immunotherapy. Median progression free survival on cabozantinib therapy was 2.1 months (95% CI: 1.3-3.9) and median overall survival from time of cabozantinib initiation was 7.7 months (95% CI: 5.3-14.9). (4) Conclusion: The optimal sequencing of therapy for patients with advanced HCC following progression on immunotherapy remains unknown. Our study demonstrates that patients may benefit from treatment with cabozantinib following progression on immunotherapy.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Multisite institutional study of efficacy and safety of cabozantinib following immunotherapy in patients with advanced hepatocellular carcinoma.
    Palmer, Mathias Earl
    Storandt, Michael H.
    Gile, Jennifer
    Zemla, Tyler J.
    Bekaii-Saab, Tanios S.
    Jin, Zhaohui
    Tran, Nguyen H.
    Mahipal, Amit
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 559 - 559
  • [2] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
    Abou-Alfa, G. K.
    Meyer, T.
    Cheng, A. -L.
    El-Khoueiry, A. B.
    Rimassa, L.
    Ryoo, B. -Y.
    Cicin, I.
    Merle, P.
    Chen, Y. H.
    Park, J. -W.
    Blanc, J. -F.
    Bolondi, L.
    Klumpen, H. -J.
    Chan, S. L.
    Zagonel, V.
    Pressiani, T.
    Ryu, M. -H.
    Venook, A. P.
    Hessel, C.
    Borgman-Hagey, A. E.
    Schwab, G.
    Kelley, R. K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01): : 54 - 63
  • [3] Cabozantinib in the treatment of advanced hepatocellular carcinoma patients
    Klank-Sokolowska, Ewa
    Kucharewicz, Mariola
    Wojtukiewicz, Marek Z.
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (04): : 195 - 201
  • [4] Cabozantinib for advanced hepatocellular carcinoma
    Baker, Holly
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (09): : 600 - 600
  • [5] Cabozantinib for advanced hepatocellular carcinoma
    Kudo, Masatoshi
    [J]. HEPATOBILIARY SURGERY AND NUTRITION, 2019, 8 (02) : 153 - 156
  • [6] Cabozantinib for advanced hepatocellular Carcinoma
    Alakus, Hakan
    Kuetting, Fabian
    Bruns, Christiane
    [J]. ONKOLOGE, 2018, 24 (11): : 924 - 926
  • [7] Cabozantinib: A Review in Advanced Hepatocellular Carcinoma
    Deeks, Emma D.
    [J]. TARGETED ONCOLOGY, 2019, 14 (01) : 107 - 113
  • [8] Cabozantinib: A Review in Advanced Hepatocellular Carcinoma
    Emma D. Deeks
    [J]. Targeted Oncology, 2019, 14 : 107 - 113
  • [9] Outcome of receiving lenvatinib following immunotherapy in patients with advanced hepatocellular carcinoma.
    Gile, Jennifer
    Palmer, Mathias Earl
    Storandt, Michael H.
    Bekaii-Saab, Tanios S.
    Tran, Nguyen H.
    Mahipal, Amit
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 507 - 507
  • [10] Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis
    Shlomai, Amir
    Leshno, Moshe
    Goldstein, Daniel A.
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12